FDA Grants Fast Track Status to Celsion’s GEN-1 for Advanced Cancer
Ovarian Cancer News Today
by Patricia Inacio PhD
3y ago
Celsion‘s immunotherapy candidate, GEN-1, has received fast track designation from the U.S. Food and Drug Administration (FDA) for advanced ovarian cancer. This designation helps speed the approval of potential medicines that address unmet medical needs in serious or life-threatening conditions. It grants greater access to FDA input throughout the regulatory process and makes GEN-1 eligible for accelerated approval and priority review, provided it meets certain criteria. “Fast Track designation is an important step in developing GEN-1 for advanced ovarian cancer,” Michael H. Tardugno, Celsion ..read more
Visit website
She ROCKS Raises $100K to Support Early Work Into Stem Cell Therapy
Ovarian Cancer News Today
by Patricia Inacio PhD
3y ago
She ROCKS, an organization working for earlier diagnosis and better treatments for ovarian cancer, raised $100,000 through recent virtual luncheon fundraisers to support ongoing research into a potential stem cell-based therapy. Since its inception in 2014, She ROCKS has contributed more than $1 million to support ovarian cancer research underway at the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center. The ongoing study, called MASCOT (for Manufacturing and Analysis of Stem Cells from Skin Cells for Ovarian Cancer Treatment), aims to create stem cells from t ..read more
Visit website
Progesterone May Help Drive Spread of Ovarian Cancer, Preclinical Study Shows
Ovarian Cancer News Today
by Marisa Wexler MS
3y ago
The hormone progesterone helps to drive the development of metastatic ovarian cancer, and blocking progesterone signaling may be a useful strategy for preventing the cancer, a study in mice suggests. The study, “Targeting progesterone signaling prevents metastatic ovarian cancer,” was published in PNAS. High-grade serous carcinoma (HGSC) is the most common, and most deadly, form of ovarian cancer. Although considered an ovarian cancer, most HGSC tumors don’t arise from the ovaries themselves, but rather from the fallopian tubes (which connect the ovaries to the uterus). Metastasis — whe ..read more
Visit website
InVivo Analytics Granted $1.7M to Advance Preclinical 3D Imaging
Ovarian Cancer News Today
by Patricia Inacio PhD
3y ago
InVivo Analytics has received $1.7 million to develop and commercialize its next-generation fluorescence imaging device, called InVivoFLUOR, for 3D monitoring of immune cell migration in animal models of cancer, the company announced in a press release. Company researchers plan to validate the system on a mouse model of ovarian cancer. Animals will be treated with an advanced immunotherapy, developed at the the University of Washington, that activates T-cells against ovarian cancer cells. The grant is part of the National Cancer Institute’s Small Business Innovation Research Phase II program ..read more
Visit website
ENB-003 with Keytruda Shows Promise Against Advanced Solid Tumors
Ovarian Cancer News Today
by Joana Carvalho
3y ago
ENB Therapeutics’ lead novel anti-cancer therapy, ENB-003, was found to be safe and showed promising anti-tumor activity, when given in combination with Keytruda (pembrolizumab), to adults with different types of advanced solid malignancies, including ovarian cancer and melanoma. These are the early findings of an open-label Phase 1/2 trial (NCT04205227) that has recently finished dosing the third group of patients participating in its dose-escalation phase. “We are very excited to observe the continued safety of our combination regimen as well as early efficacy signals as we escalate the do ..read more
Visit website
€15M EU Project Seeks to Improve Personalized Medicine Options
Ovarian Cancer News Today
by Forest Ray PhD
3y ago
The European Union is providing nearly €15 million ($18.1 million) over five years to improve personalized medicine options for people with drug-resistant high-grade serous ovarian cancer. The DECIDER project, funded by the EU’s Horizon 2020 research and innovation program, will apply artificial intelligence methods to develop new diagnostic tools to identify — earlier and more accurately — those patients whose cancer is not responding to treatments. The goal is to find effective drug combinations for these individuals. “Cancer is one of the leading causes of mortality in the world and as th ..read more
Visit website
Early Trial Starts Testing Recommended STRO-002 Dose for Advanced Cancer
Ovarian Cancer News Today
by Diana Campelo Delgado
3y ago
Sutro Biopharma‘s Phase 1 clinical trial has begun testing the recommended dose of STRO-002 in heavily pretreated patients with advanced ovarian cancer. “We are excited to be part of the STRO-002-GM1 dose-expansion study and to provide additional clinical data to show the potential of this therapeutic for ovarian patients with limited treatment options,” Lainie Martin, MD, trial investigator and leader of the gynecology/oncology program at the Hospital of the University of Pennsylvania, said in a press release. A total of 20 ovarian cancer patients, being enrolled at multiple sites in t ..read more
Visit website
Blocking Glutamine Metabolism May Help Combat OCCC Tumors
Ovarian Cancer News Today
by Joana Carvalho
3y ago
Ovarian cancer cells harboring mutations in the ARID1A tumor suppressor gene tend to use the amino acid glutamine as a source of energy more often, making the cells more vulnerable to compounds that interfere with glutamine metabolism, scientists found. As proof, they demonstrated that a compound that inactivates glutaminase (the enzyme that normally breaks down glutamine) can prevent tumor growth in mouse models of ovarian clear cell carcinomas (OCCC) whose cancer cells harbor ARID1A mutations. “Our findings suggest that glutaminase inhibitors warrant further studies as a standalone or comb ..read more
Visit website
BioVaxys Advances Plans to Bring Vaccine to Clinic
Ovarian Cancer News Today
by Joana Carvalho
3y ago
BioVaxys is planning to request that its investigational vaccine for ovarian cancer, BVX-0918A, be approved for compassionate use in people with advanced ovarian cancer in Europe. The company also plans to file requests to U.S. and European regulatory health authorities requesting authorization to pursue clinical trials of BVX-0918A in the coming months. As part of its plan to accelerate the development of BVX-0918A, BioVaxys is already having discussions with its designated contract manufacturing organization, and expects to enter a contract in the coming months, the company announced in a ..read more
Visit website
Combining Imaging Methods May Reduce Need for Tumor Biopsies
Ovarian Cancer News Today
by Marisa Wexler MS
3y ago
Combining two imaging methods can provide a more accurate sampling of single tumors — like those found in ovarian cancer — thus allowing doctors to capture the diverse cancer cells in the tumor with fewer biopsies, a new study found. The study, “Ultrasound-guided targeted biopsies of CT-based radiomic tumour habitats: technical development and initial experience in metastatic ovarian cancer,” was published in European Radiology. One of the challenges in treating cancer is that a single tumor is usually heterogeneous, meaning it contains many different kinds of cells. Not only are there ..read more
Visit website

Follow Ovarian Cancer News Today on FeedSpot

Continue with Google
Continue with Apple
OR